Although BRAF mutations are uncommon, they represent an important therapeutic target due to the availability of individualized therapies in clinical use for melanoma and the promising results reported in ongoing clinical trials for NSCLC patients [33]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.